sur ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE)
OSE Immunotherapeutics: Reorganization of the Board of Directors
On September 30, 2025, OSE Immunotherapeutics held its Annual General Meeting in Paris. This event saw a complete renewal of its Board of Directors. Shareholders voted to appoint several members, including Caroline Mary, Pascale Briand, and Alexis Peyroles. Dr. Markus Cappel was elected Chairman of the Board of Directors.
Dr. Cappel, with thirty years of experience in biotechnology, expresses his enthusiasm for collaborating with the OSE Immunotherapeutics team to develop a robust pipeline of drug candidates. He notably played a key role in Amgen's acquisition of ChemoCentryx.
This reorganization aims to consolidate OSE Immunotherapeutics' position in the field of immunotherapy, a constantly evolving sector.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ORPHAN SYNERGY EUROPE-PHARMA